Loading
Tobemstomig / Pembrolizumab / Breast Cancer · Phase 2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registry record for a randomized comparison of tobemstomig plus nab-paclitaxel versus pembrolizumab plus nab-paclitaxel in previously untreated, PD-L1-positive locally advanced or metastatic triple-negative breast cancer. No results have been posted to the registry; the study is closed to recruitment but outcome data are not yet available, precluding assessment of efficacy or safety.
Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Breast Cancer; age from 18 Years. Intervention: Arm A. Compared with: Arm B — Active Comparator. n = 83. 37 sites across 16 countries.
This is a Phase 2 registry record for a randomized comparison of tobemstomig plus nab-paclitaxel versus pembrolizumab plus nab-paclitaxel in previously untreated, PD-L1-positive locally advanced or metastatic triple-negative breast cancer. No results have been posted to the registry; the study is closed to recruitment but outcome data are not yet available, precluding assessment of efficacy or safety.
No results posted; outcomes, effect sizes, and safety data are not reported in this registry record.
This trial may establish whether tobemstomig, a novel immunotherapy candidate, offers efficacy or safety advantages over pembrolizumab when combined with nab-paclitaxel in TNBC. However, interpretation must await disclosure of results; no clinical recommendations can be drawn from this registry record.
This is a Phase 2 trial registry record with no posted results; the study is active but not recruiting, so outcomes remain unreported and cannot be assessed.
As stated by the source record.
Quoted from the source exactly as published.
This trial may establish whether tobemstomig, a novel immunotherapy candidate, offers efficacy or safety advantages over pembrolizumab when combined with nab-paclitaxel in TNBC. However, interpretation must await disclosure of results; no clinical recommendations can be drawn from this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05852691). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 83 participants (ACTUAL). Conditions: Breast Cancer. Interventions: DRUG: Tobemstomig; DRUG: Pembrolizumab; DRUG: Nab-Paclitaxel. Primary outcome measures: Progression-Free Survival (PFS) , From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months). Brief summary: The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.